Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 10 2019
Historique:
pubmed: 4 7 2019
medline: 22 1 2021
entrez: 4 7 2019
Statut: ppublish

Résumé

Genome-wide association studies (GWASs) in European populations have identified more than 100 schizophrenia-associated loci. A schizophrenia GWAS in a unique Indian population offers novel findings. To discover and functionally evaluate genetic loci for schizophrenia in a GWAS of a unique Indian population. This GWAS included a sample of affected individuals, family members, and unrelated cases and controls. Three thousand ninety-two individuals were recruited and diagnostically ascertained via medical records, hospitals, clinics, and clinical networks in Chennai and surrounding regions. Affected participants fulfilled DSM-IV diagnostic criteria for schizophrenia. Unrelated control participants had no personal or family history of psychotic disorder. Recruitment, genotyping, and analysis occurred in consecutive phases beginning January 1, 2001. Recruitment was completed on February 28, 2018, and genotyping and analysis are ongoing. Associations of single-nucleotide polymorphisms and gene expression with schizophrenia. The study population included 1321 participants with schizophrenia, 885 family controls, and 886 unrelated controls. Among participants with schizophrenia, mean (SD) age was 39.1 (11.4) years, and 52.7% were male. This sample demonstrated uniform ethnicity, a degree of inbreeding, and negligible rates of substance abuse. A novel genome-wide significant association was observed between schizophrenia and a chromosome 8q24.3 locus (rs10866912, allele A; odds ratio [OR], 1.27 [95% CI, 1.17-1.38]; P = 4.35 × 10-8) that attracted support in the schizophrenia Psychiatric Genomics Consortium 2 data (rs10866912, allele A; OR, 1.04 [95% CI, 1.02-1.06]; P = 7.56 × 10-4). This locus has undergone natural selection, with the risk allele A declining in frequency from India (approximately 72%) to Europe (approximately 43%). rs10866912 directly modifies the abundance of the nicotinate phosphoribosyltransferase gene (NAPRT1) transcript in brain cortex (normalized effect size, 0.79; 95% CI, 0.6-1.0; P = 5.8 × 10-13). NAPRT1 encodes a key enzyme for niacin metabolism. In Indian lymphoblastoid cell lines, (risk) allele A of rs10866912 was associated with NAPRT1 downregulation (AA: 0.74, n = 21; CC: 1.56, n = 17; P = .004). Preliminary zebrafish data further suggest that partial loss of function of NAPRT1 leads to abnormal brain development. Bioinformatic analyses and cellular and zebrafish gene expression studies implicate NAPRT1 as a novel susceptibility gene. Given this gene's role in niacin metabolism and the evidence for niacin deficiency provoking schizophrenialike symptoms in neuropsychiatric diseases such as pellagra and Hartnup disease, these results suggest that the rs10866912 genotype and niacin status may have implications for schizophrenia susceptibility and treatment.

Identifiants

pubmed: 31268507
pii: 2737033
doi: 10.1001/jamapsychiatry.2019.1335
pmc: PMC6613304
doi:

Substances chimiques

Niacin 2679MF687A
Pentosyltransferases EC 2.4.2.-
nicotinate phosphoribosyltransferase EC 6.3.4.21

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1026-1034

Subventions

Organisme : Wellcome Trust
ID : 208806/Z/17/Z
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : R35 GM118335
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109536
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Nat Genet. 2016 May;48(5):481-7
pubmed: 27019110
Science. 2012 Jul 6;337(6090):100-4
pubmed: 22604722
Nature. 2011 Oct 26;478(7370):483-9
pubmed: 22031440
J Neurochem. 2011 Oct;119(2):275-82
pubmed: 21848658
Biochimie. 2012 Feb;94(2):300-9
pubmed: 21742010
Nat Rev Neurosci. 2016 Feb;17(2):125-34
pubmed: 26763624
Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1345-54
pubmed: 18821565
Am J Hum Genet. 2017 Apr 6;100(4):635-649
pubmed: 28366442
Nat Neurosci. 2016 Nov;19(11):1442-1453
pubmed: 27668389
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Science. 2015 Dec 4;350(6265):1208-13
pubmed: 26785480
Wiley Interdiscip Rev Dev Biol. 2015 Jan-Feb;4(1):17-32
pubmed: 25339593
Bioinformatics. 2017 Jan 15;33(2):248-255
pubmed: 27663501
PLoS Genet. 2014 Oct 30;10(10):e1004722
pubmed: 25357204
Gen Hosp Psychiatry. 2008 Nov-Dec;30(6):581-4
pubmed: 19061687
Am J Hum Genet. 2017 Jul 6;101(1):5-22
pubmed: 28686856
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Bioinformatics. 2017 Jul 15;33(14):i379-i388
pubmed: 28881976
Bioinformatics. 2017 Feb 15;33(4):594-595
pubmed: 27742697
N Engl J Med. 2017 Aug 10;377(6):544-552
pubmed: 28792876
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4
pubmed: 7944874
Am J Hum Genet. 2013 Sep 5;93(3):463-70
pubmed: 23954163
PLoS Med. 2005 May;2(5):e141
pubmed: 15916472
Nat Commun. 2015 Jun 08;6:7378
pubmed: 26051838
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Arch Gen Psychiatry. 2003 Dec;60(12):1187-92
pubmed: 14662550
Mol Psychiatry. 2018 May;23(5):1261-1269
pubmed: 29038599
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Aust N Z J Psychiatry. 2009 Jun;43(6):561-70
pubmed: 19440889
PLoS Genet. 2015 Jul 22;11(7):e1005371
pubmed: 26201053
Nat Genet. 2012 Feb 19;44(3):247-50
pubmed: 22344220
Hum Mol Genet. 2016 May 1;25(9):1728-38
pubmed: 26908606

Auteurs

Sathish Periyasamy (S)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Sujit John (S)

Schizophrenia Research Foundation, Chennai, India.

Raman Padmavati (R)

Schizophrenia Research Foundation, Chennai, India.

Preeti Rajendren (P)

Schizophrenia Research Foundation, Chennai, India.

Priyadarshini Thirunavukkarasu (P)

Schizophrenia Research Foundation, Chennai, India.

Jacob Gratten (J)

Mater Research Institute and University of Queensland, Translational Research Institute, Brisbane, Australia.
Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Anna Vinkhuyzen (A)

Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Allan McRae (A)

Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Elizabeth G Holliday (EG)

Public Health Program, Hunter Medical Research Institute, Newcastle, Australia.

Dale R Nyholt (DR)

QIMR Berghofer Medical Research Institute, Brisbane, Australia.
School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.

Derek Nancarrow (D)

Department of Surgery, University of Michigan, Ann Arbor.

Andrew Bakshi (A)

Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Gibran Hemani (G)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Medical Research Council Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, Bristol, United Kingdom.

Deborah Nertney (D)

Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Heather Smith (H)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Cheryl Filippich (C)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Kalpana Patel (K)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Javed Fowdar (J)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.

Duncan McLean (D)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Srinivasan Tirupati (S)

Psychiatric Rehabilitation Service, Hunter New England Mental Health, Newcastle, Australia.

Arunkumar Nagasundaram (A)

Athma Hospitals and Research, Tiruchirapalli, India.

Prasad Rao Gundugurti (PR)

Asha Hospital, Hyderabad, India.

Krishnamurthy Selvaraj (K)

Vazhikatti Mental Health Centre and Research Institute, Coimbatore, India.

Jayaprakash Jegadeesan (J)

Manathin Maiyam Hospital, Erode, India.

Lynn B Jorde (LB)

Department of Human Genetics, University of Utah, Salt Lake City.

Naomi R Wray (NR)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Matthew A Brown (MA)

Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia.

Rachel Suetani (R)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Jean Giacomotto (J)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Rangaswamy Thara (R)

Schizophrenia Research Foundation, Chennai, India.

Bryan J Mowry (BJ)

Queensland Brain Institute, University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, West Moreton Hospital and Health Service, University of Queensland, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH